Suven Pharmaceuticals Appoints Vivek Sharma as New Executive Chairman
2 Sources
2 Sources
[1]
Suven Pharmaceuticals names Vivek Sharma as executive chairman
Suven Pharma, backed by Advent International, has appointed Vivek Sharma as the new executive chairman effective September 20. Sharma brings extensive experience in managing CDMO businesses and will focus on global expansion. The former chairman, Annaswamy Vaidheesh, transitions to vice-chair of Suven's Advisory council.PE firm Advent International-backed Suven Pharma on Thursday announced the appointment of Vivek Sharma as the new executive chairman, effective September 20, as the incumbent Annaswamy Vaidheesh decides to transition from the Board and becomes the vice-chair of Suven's Advisory council. Sharma is known for his managing CDMO businesses, with leadership roles as CEO of Piramal Pharma solutions (2014-19) and as chairman & CEO of US-based Adare Pharma solutions, a technology CDMO business (2020-22). He was also CEO of Decision Resources Group, a healthcare analytics company (2019-20) once owned by Piramal Group and CEO of Saama, an AI clinical analytics company (2022-24). Sharma earned an executive MBA from the Thunderbird School of Global Management. He is also a Chartered Accountant and a Certified Public Accountant (CPA). Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform. "We are confident that the business will immensely benefit from Vivek (Sharma)'s many years of CDMO and leadership experience, which will enable us to unlock many future growth opportunities," said Pankaj Patwari, non-exec director, Suven and MD of Advent International said. In his role as the executive chairman, Vaidheesh has successfully overseen the management transition at Suven, built a professional team and led the development of the 5-year strategy. He has also set the stage for the proposed merger of Cohance Lifesciences into Suven (ongoing) and has successfully led the acquisition of Sapala Organics. Advent is building the Hyderabad-based Suven Pharma into a CDMO and API platform through a string of acquisitions
[2]
Suven Pharmaceuticals names Vivek Sharma as new Executive Chairman
Suven Pharmaceuticals appointed Vivek Sharma as the new Executive Chairman with effect from September 20, 2024 as Vaidheesh Annaswamy decided to transition from the Board and becomes the Vice-Chair of Suven's advisory council. ''Vivek brings tremendous CDMO and leadership expertise to Suven, acquired across his roles as CEO of Piramal Pharma solutions (2014-19) and as Chairman & CEO of Adare Pharma solutions, a technology CDMO business (2020-22),'' the company said in a release. He was also CEO of Decision Resources Group, a healthcare analytics company (2019-20) and CEO of Saama, an AI clinical analytics company (2022-24). Vivek was recognised as 'Global CEO of the Year' by CPhI Pharma Awards in 2015. "Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform,'' the release said. Vivek earned an Executive MBA from the Thunderbird School of Global Management. He is also a Chartered Accountant and a Certified Public Accountant (CPA). SHARE Copy linkEmailFacebookTwitterTelegramLinkedInWhatsAppRedditPublished on September 19, 2024
Share
Share
Copy Link
Suven Pharmaceuticals, an Indian pharmaceutical company, has named Vivek Sharma as its new Executive Chairman. This appointment marks a significant leadership change for the company.
Appointment of New Executive Chairman
Suven Pharmaceuticals, a prominent player in the Indian pharmaceutical industry, has announced a significant leadership change. The company has appointed Vivek Sharma as its new Executive Chairman, effective immediately
1
. This move comes as part of the company's strategic efforts to strengthen its management team and drive future growth.Background of Vivek Sharma
Vivek Sharma brings a wealth of experience to his new role at Suven Pharmaceuticals. He has previously served as the CEO of Piramal Pharma Solutions, a contract development and manufacturing organization (CDMO)
2
. His extensive background in the pharmaceutical industry is expected to be a valuable asset for Suven as it navigates the competitive landscape of the sector.Implications for Suven Pharmaceuticals
The appointment of Sharma as Executive Chairman is seen as a strategic move for Suven Pharmaceuticals. With his experience in the CDMO space, Sharma is well-positioned to guide the company's growth in this crucial segment of the pharmaceutical industry
1
. His leadership is expected to bring fresh perspectives and potentially new directions for the company's operations and market strategies.Industry Context
This leadership change comes at a time when the pharmaceutical industry is experiencing significant transformations. The CDMO sector, in particular, has been growing rapidly, driven by increasing outsourcing trends in drug development and manufacturing
2
. Suven Pharmaceuticals, with its focus on this area, stands to benefit from Sharma's expertise in navigating these industry dynamics.Related Stories
Company's Future Outlook
Under Sharma's leadership, Suven Pharmaceuticals is likely to focus on expanding its CDMO capabilities and exploring new growth opportunities. The company may look to leverage Sharma's industry connections and knowledge to forge new partnerships and enhance its market position
1
. Shareholders and industry observers will be keenly watching how this leadership change influences the company's strategic direction and financial performance in the coming months.Reactions and Expectations
While the official announcement has been made, detailed reactions from industry analysts and stakeholders are yet to emerge. However, the appointment is generally seen as a positive move, given Sharma's track record in the pharmaceutical industry
2
. The market's response to this news will be an important indicator of the perceived impact of this leadership change on Suven Pharmaceuticals' future prospects.References
Summarized by
Navi
[1]
Related Stories
Weekly Highlights
Weekly Highlights
Today's Top Stories
Your Daily Dose of Curated AI News
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Spend less time searching for the latest in AI and get straight to action.
